Skip to main content

Table 1 Clinical data in malignant and nonmalignant IPMNs

From: The association between serum ferritin levels and malignant intraductal papillary mucinous neoplasms

  Total
(n = 151)
Malignant IPMNs
(n = 47)
Nonmalignant IPMNs
(n = 104)
p
Age 63.28 ± 9.47 63.59 ± 8.99 62.60 ± 10.50 0.55
Size 3.69 ± 1.98 3.93 ± 1.63 3.58 ± 2.11 0.34
Sex (male/female) 84/47 29/11 55/36 0.28
Dysplasia
  Low-intermediate grade 104 / 104  
  High-grade 24 24 0  
  Invasion 23 13 0  
Type     <  0.01
  Main 24 16 8  
  Branch 73 9 64  
  Mixed 54 22 32  
Location     0.15
  Head-neck 95 34 61  
  Body and Tail 56 13 43  
CEA (ng/ml) 3.57 ± 3.61 4.75 ± 5.65 3.03 ± 1.95 0.09
  CEA > 5.0 24 10 14 0.22
CA19–9 (U/ml) 48.68 ± 228.65 99.04 ± 396.08 26.19 ± 70.67 0.002
  > 37 29 17 12 <  0.001
Ferritin (ng/ml) 275.03 ± 284.65 370.58 ± 358.19 231.84 ± 233.76 0.001
  > 232 60 26 34 0.009
MPD diameter 0.61 ± 0.41 0.90 ± 0.49 0.48 ± 0.29 <  0.001
Chronic cholecystitis 56 17 39 0.87
Pancreatitis 3 0 3 0.24
Abdominal Symptoms 67 23 44 0.92
Diabetes 23 9 14 0.13
Lymph node metastasis (yes vs no) 2 2 0 0.09
Peripancreatic extension 5 5 0 0.003
Mural nodule 17 13 4 <  0.01
  1. Malignant IPMNs were defined as those with high grade dysplasia and associated invasive carcinoma
  2. CA 19–9 carbohydrate antigen 19–9; CEA carcinoembryonic antigen; MPD main pancreatic duct